Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Irritable Bowel Syndrome

Free Subscription Articles published in Gut Retrieve available abstracts of 39 articles: HTML format

Single Articles

October 2025
1. SHIHA MG, Manza F, Figueroa-Salcido OG, Ontiveros N, et al
   Global prevalence of self-reported non-coeliac gluten and wheat sensitivity: a systematic review and meta-analysis.
   Gut. 2025 Oct 28:gutjnl-2025-336304. doi: 10.1136/gutjnl-2025-336304.
   PubMed     Abstract available
   
   
   
2. TANNOUS S, Husein DM, Naim HY
   Congenital sucrase-isomaltase mutations worsen IBS-linked V15F dysfunction and trafficking.
   Gut. 2025 Oct 21:gutjnl-2025-336813. doi: 10.1136/gutjnl-2025-336813.
   PubMed    
   
   
   
3. RUILOVA SOSORANGA E, Tack J
   Insulin-like peptide 5: a new key player in IBS with diarrhoea and bile acid malabsorption?
   Gut. 2025 Oct 17:gutjnl-2025-336390. doi: 10.1136/gutjnl-2025-336390.
   PubMed    
   
   
   
4. SCHMELTER F, Schroder T, Laumonnier Y, Bischoff SC, et al
   Impaired glucose metabolism in irritable bowel syndrome: personalised low-glycaemic diet as potential therapeutic target.
   Gut. 2025 Oct 5:gutjnl-2025-336797. doi: 10.1136/gutjnl-2025-336797.
   PubMed    
   
   
   September 2025
5. ZAMFIR-TARANU A, Loscher BS, Franke A, Bonfiglio F, et al
   Sucrase-isomaltase hypomorphic variant Val15Phe affects the response to a sucrose challenge test in patients with IBS.
   Gut. 2025 Sep 10:gutjnl-2025-336393. doi: 10.1136/gutjnl-2025-336393.
   PubMed    
   
   
   July 2025
6. BANNON CA, Walters JRF, Wu T, Kay RG, et al
   Insulin-like peptide 5 is released in response to bile acid in the rectum and is associated with diarrhoea severity in patients with bile acid diarrhoea.
   Gut. 2025 Jul 23:gutjnl-2025-335393. doi: 10.1136/gutjnl-2025-335393.
   PubMed     Abstract available
   
   
   February 2025
7. DECRAECKER L, Cuende Estevez M, Van Remoortel S, Quan R, et al
   Characterisation of MRGPRX2(+) mast cells in irritable bowel syndrome.
   Gut. 2025 Feb 23:gutjnl-2024-334037. doi: 10.1136/gutjnl-2024-334037.
   PubMed     Abstract available
   
   
   January 2025
8. WRIGHT-HUGHES A, Ow PL, Alderson SL, Ridd MJ, et al
   Predictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype: post hoc analyses from the ATLANTIS trial.
   Gut. 2025 Jan 25:gutjnl-2024-334490. doi: 10.1136/gutjnl-2024-334490.
   PubMed     Abstract available
   
   
   
9. 
   Correction: Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis.
   Gut. 2025;74:e12.
   PubMed    
   
   
   November 2024
10. WELLENS J, Sabino J, Vanuytsel T, Tack J, et al
    Recent advances in clinical practice: mastering the challenge-managing IBS symptoms in IBD.
    Gut. 2024 Nov 12:gutjnl-2024-333565. doi: 10.1136/gutjnl-2024-333565.
    PubMed     Abstract available
    
    
    October 2024
11. WILKINSON-SMITH V, Scott M, Menys A, Wiklendt L, et al
    Combined MRI, high-resolution manometry and a randomised trial of bisacodyl versus hyoscine show the significance of an enlarged colon in constipation: the RECLAIM study.
    Gut. 2024 Oct 22:gutjnl-2024-332755. doi: 10.1136/gutjnl-2024-332755.
    PubMed     Abstract available
    
    
    July 2024
12. PORCARI S, Ingrosso MR, Maida M, Eusebi LH, et al
    Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis.
    Gut. 2024 Jul 16:gutjnl-2023-331835. doi: 10.1136/gutjnl-2023-331835.
    PubMed     Abstract available
    
    
    
13. TORICES L, Zamfir-Taranu A, Esteban-Blanco C, Bozzarelli I, et al
    Human CAZyme genes polymorphism and risk of IBS: a population-based study.
    Gut. 2024 Jul 5:gutjnl-2024-333056. doi: 10.1136/gutjnl-2024-333056.
    PubMed    
    
    
    May 2024
14. FORD AC, Staudacher HM, Talley NJ
    Postprandial symptoms in disorders of gut-brain interaction and their potential as a treatment target.
    Gut. 2024 May 2:gutjnl-2023-331833. doi: 10.1136/gutjnl-2023-331833.
    PubMed     Abstract available
    
    
    February 2024
15. HO FF, Sun H, Zheng H, Wong DCN, et al
    Association of healthy lifestyle behaviours with incident irritable bowel syndrome: a large population-based prospective cohort study.
    Gut. 2024 Feb 20:gutjnl-2023-331254. doi: 10.1136/gutjnl-2023-331254.
    PubMed     Abstract available
    
    
    
16. FORD AC
    Ebastine for the treatment of irritable bowel syndrome: old drug, new tricks?
    Gut. 2024 Feb 1:gutjnl-2024-331927. doi: 10.1136/gutjnl-2024-331927.
    PubMed    
    
    
    January 2024
17. DECRAECKER L, De Looze D, Hirsch DP, De Schepper H, et al
    Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial.
    Gut. 2024 Jan 8:gutjnl-2023-331634. doi: 10.1136/gutjnl-2023-331634.
    PubMed     Abstract available
    
    
    November 2023
18. TUN HM, Peng Y, Massimino L, Sin ZY, et al
    Gut virome in inflammatory bowel disease and beyond.
    Gut. 2023 Nov 10:gutjnl-2023-330001. doi: 10.1136/gutjnl-2023-330001.
    PubMed     Abstract available
    
    
    October 2023
19. JUZENAS S, Ellinghaus D, Sanna S, Franke A, et al
    Mendelian randomisation shows diverticular disease and irritable bowel syndrome increase the risk of haemorrhoidal disease.
    Gut. 2023 Oct 9:gutjnl-2023-330364. doi: 10.1136/gutjnl-2023-330364.
    PubMed    
    
    
    August 2023
20. KONINGS B, Villatoro L, Van den Eynde J, Barahona G, et al
    Gastrointestinal syndromes preceding a diagnosis of Parkinson's disease: testing Braak's hypothesis using a nationwide database for comparison with Alzheimer's disease and cerebrovascular diseases.
    Gut. 2023 Aug 24:gutjnl-2023-329685. doi: 10.1136/gutjnl-2023-329685.
    PubMed     Abstract available
    
    
    March 2023
21. DAI C, Huang YH, Jiang M
    Post-COVID-19 irritable bowel syndrome.
    Gut. 2023 Mar 10:gutjnl-2023-329714. doi: 10.1136/gutjnl-2023-329714.
    PubMed    
    
    
    
22. ZAMFIR-TARANU A, Loscher BS, Husein DM, Hoter A, et al
    Sucrase-isomaltase genotype and response to a starch-reduced and sucrose-reduced diet in IBS-D patients.
    Gut. 2023 Mar 6:gutjnl-2023-329695. doi: 10.1136/gutjnl-2023-329695.
    PubMed    
    
    
    February 2023
23. BULMER D
    Neuroactive changes in the bowel of patients with IBS on low FODMAP diet: another piece of the puzzle.
    Gut. 2023 Feb 3:gutjnl-2022-329184. doi: 10.1136/gutjnl-2022-329184.
    PubMed    
    
    
    
24. HOUDEVILLE C, Chartier S, Delaye M, Fabiani B, et al
    White small bowel in a patient with chronic diarrhoea.
    Gut. 2023;72:225-324.
    PubMed    
    
    
    January 2023
25. ZHU Z, Chen X, Wang C, Zhang S, et al
    Haemorrhoidal disease reduces the risk of diverticular disease and irritable bowel syndrome: a Mendelian randomisation study.
    Gut. 2023 Jan 24:gutjnl-2022-329307. doi: 10.1136/gutjnl-2022-329307.
    PubMed    
    
    
    
26. VANUYTSEL T, Bercik P, Boeckxstaens G
    Understanding neuroimmune interactions in disorders of gut-brain interaction: from functional to immune-mediated disorders.
    Gut. 2023 Jan 19:gutjnl-2020-320633. doi: 10.1136/gutjnl-2020-320633.
    PubMed     Abstract available
    
    
    
27. BOUSABA J, Zheng T, Dilmaghani S, Johnson S, et al
    Effect of rapid colonic transit on stool microbiome and short-chain fatty acids in diarrhoea-predominant irritable bowel syndrome.
    Gut. 2023 Jan 19:gutjnl-2022-329359. doi: 10.1136/gutjnl-2022-329359.
    PubMed    
    
    
    December 2022
28. TUCK CJ, Abu Omar A, De Palma G, Osman S, et al
    Changes in signalling from faecal neuroactive metabolites following dietary modulation of IBS pain.
    Gut. 2022 Dec 13:gutjnl-2022-327260. doi: 10.1136/gutjnl-2022-327260.
    PubMed     Abstract available
    
    
    
29. MARASCO G, Cremon C, Barbaro MR, Cacciari G, et al
    Post COVID-19 irritable bowel syndrome.
    Gut. 2022 Dec 9:gutjnl-2022-328483. doi: 10.1136/gutjnl-2022-328483.
    PubMed     Abstract available
    
    
    October 2022
30. CAMILLERI M, Boeckxstaens G
    Irritable bowel syndrome: treatment based on pathophysiology and biomarkers.
    Gut. 2022 Oct 28. pii: gutjnl-2022-328515. doi: 10.1136/gutjnl-2022-328515.
    PubMed     Abstract available
    
    
    
31. PETITFILS C, Maurel S, Payros G, Hueber A, et al
    Identification of bacterial lipopeptides as key players in IBS.
    Gut. 2022 Oct 14. pii: gutjnl-2022-328084. doi: 10.1136/gutjnl-2022-328084.
    PubMed     Abstract available
    
    
    
32. TACK J, Van den Houte K, Carbone F
    Role of the DOMINO diet application for managing IBS in primary care and beyond.
    Gut. 2022 Oct 13. pii: gutjnl-2022-328315. doi: 10.1136/gutjnl-2022-328315.
    PubMed    
    
    
    September 2022
33. JALANKA J, Gunn D, Singh G, Krishnasamy S, et al
    Postinfective bowel dysfunction following Campylobacter enteritis is characterised by reduced microbiota diversity and impaired microbiota recovery.
    Gut. 2022 Sep 28. pii: gutjnl-2021-326828. doi: 10.1136/gutjnl-2021-326828.
    PubMed     Abstract available
    
    
    
34. BALSIGER LM, Van den Houte K, Zheng T, Toth J, et al
    Genetic analyses of treatment response in primary care IBS, a pilot study.
    Gut. 2022 Sep 23. pii: gutjnl-2022-328430. doi: 10.1136/gutjnl-2022-328430.
    PubMed    
    
    
    July 2022
35. CAMILLERI M
    Fifty-point IBS-SSS responders but persistence of moderate severity IBS in over 40% of those on diet.
    Gut. 2022 Jul 26. pii: gutjnl-2022-328211. doi: 10.1136/gutjnl-2022-328211.
    PubMed    
    
    
    June 2022
36. HOWELL CA, Kemppinen A, Allgar V, Dodd M, et al
    Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D).
    Gut. 2022 Jun 27. pii: gutjnl-2022-327293. doi: 10.1136/gutjnl-2022-327293.
    PubMed     Abstract available
    
    
    
37. REJ A, Sanders DS, Aziz I
    Further research needed to determine first-line therapy for IBS in primary care.
    Gut. 2022 Jun 22. pii: gutjnl-2022-328047. doi: 10.1136/gutjnl-2022-328047.
    PubMed    
    
    
    May 2022
38. CAMILLERI M, Carlson P, BouSaba J, McKinzie S, et al
    Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea.
    Gut. 2022 May 17. pii: gutjnl-2022-327471. doi: 10.1136/gutjnl-2022-327471.
    PubMed     Abstract available
    
    
    April 2022
39. CARBONE F, Van den Houte K, Besard L, Tack C, et al
    Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute.
    Gut. 2022 Apr 28. pii: gutjnl-2021-325821. doi: 10.1136/gutjnl-2021-325821.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Irritable Bowel Syndrome is free of charge.